Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Investor presentation and Q&A

26th Jun 2026 15:00

RNS Number : 0184K
OptiBiotix Health PLC
26 June 2026
 

OptiBiotix Health plc

("OptiBiotix", the "Company" or the "Group")

 

Investor presentation and Q&A

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces that, further to its successful SweetBiotix sampling on 24 June 2026, Stephen O'Hara, CEO of OptiBiotix will provide a live presentation to investors via its Investor Hub platform on Thursday 2 July 2026 at 2pm (BST).

 

The event will provide investors an overview of the commercial progress of its first-generation products, routes to market for its second generation products, and discuss the feedback from its successful investor sampling of its first SweetBiotix product.

Interested investor should register to attend via this link: https://optibiotix.com/webinars/PQ55VP-optibiotix-investor-webinar

 

View the full announcement and submit questions to management via our website: https://optibiotix.com/link/r6g3wP

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

 

Stephen O'Hara, Chief Executive

 

About OptiBiotix :  www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABXGDLXUDDGLL

Related Shares:

OptiBiotix Health
FTSE 100 Latest
Value10,508.02
Change-21.87